USE OF DAPAGLIFLOZIN (FORXIGA) IN THE MANAGEMENT OF OBESITY AND NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES
DOI:
https://doi.org/10.56238/levv16n54-080Keywords:
Dapagliflozin, Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Obesity, Integrative ReviewAbstract
This integrative review aimed to analyze scientific evidence published between 2020 and 2025 regarding the use of dapagliflozin (Forxiga®) in the management of obesity and non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). The search was conducted in PubMed, SciELO, ScienceDirect, and Consensus Academic Database, using controlled descriptors in Portuguese and English, and including clinical, experimental, and systematic review studies. The evidence analyzed indicates that dapagliflozin shows beneficial potential on glycemic and hepatic metabolism, leading to reductions in hepatic enzymes (ALT, AST, and GGT), improved insulin sensitivity, and decreased accumulation of body and liver fat. Complementary experimental studies demonstrated that the drug acts through the modulation of metabolic and inflammatory pathways, such as FXR/SHP and LXRα/SREBP-1c, reducing hepatic lipogenesis and enhancing fatty acid oxidation. Overall, the reviewed studies suggest that dapagliflozin is a safe and promising therapeutic option for the management of NAFLD in patients with T2DM, although long-term clinical trials with larger samples are still needed to validate its therapeutic potential.
Downloads
References
BALGIR, A.; SINGH, D. A comparative study of dapagliflozin and pioglitazone in improving hepatic enzymes and hepatic steatosis in type 2 diabetes mellitus with non-alcoholic steatohepatitis. International Journal of Scientific Research, [S. l.], 2025. DOI: https://doi.org/10.36106/ijsr/6302017
CHO, K. et al. Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone. Journal of Diabetes Investigation, v. 12, n. 7, p. 1272–1277, 2020. DOI: https://doi.org/10.1111/jdi.13457
DAS, C. et al. Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey. Cureus, v. 13, e14974, 2021. DOI: https://doi.org/10.7759/cureus.14974
DUAN, H.; CHEN, F. Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes. Medicine, v. 104, 2025. DOI: https://doi.org/10.1097/MD.0000000000040836
GAO, X. et al. Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes. Biomedical Reports, v. 22, 2024. DOI: https://doi.org/10.3892/br.2024.1904
HAN, T. et al. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet-induced obese mice. Adipocyte, v. 10, p. 446–455, 2021. DOI: https://doi.org/10.1080/21623945.2021.1979277
LEE, K. et al. Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: systematic review and meta-analysis. Oman Medical Journal, v. 36, e273, 2021. DOI: https://doi.org/10.5001/omj.2021.62
LIN, Y.-H. et al. Semaglutide combined with empagliflozin vs monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: study protocol for a randomized clinical trial. PLOS ONE, v. 19, 2024. DOI: https://doi.org/10.1371/journal.pone.0302155
MANTOVANI, A. et al. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, v. 11, n. 1, 2020. DOI: https://doi.org/10.3390/metabo11010022
QIAO, P. et al. Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice. Frontiers in Pharmacology, v. 13, 2022. DOI: https://doi.org/10.3389/fphar.2022.934136
SOUZA, M. T.; SILVA, M. D.; CARVALHO, R. Revisão integrativa: o que é e como fazer. Einstein, São Paulo, v. 8, n. 1, p. 102–106, 2010. DOI: https://doi.org/10.1590/s1679-45082010rw1134
SUMIDA, Y. et al. Hepatoprotective effect of SGLT2 inhibitor on nonalcoholic fatty liver disease. Diabetes Research: Open Access, v. 2020, p. 17–25, 2020. DOI: https://doi.org/10.36502/2020/droa.6159
SUN, L. et al. Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes. Acta Diabetologica, [S. l.], 2025. DOI: https://doi.org/10.1007/s00592-025-02488-1
